Back to Journals » Research and Reports in Neonatology » Volume 4

Pneumocystis jirovecii pneumonia prophylaxis for HIV-exposed neonates

Authors Bennett N

Received 21 December 2013

Accepted for publication 19 February 2014

Published 8 April 2014 Volume 2014:4 Pages 71—74


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Nicholas J Bennett

Division of Infectious Diseases and Immunology, Connecticut Childrens Medical Center, Hartford, CT, USA

Abstract: Pneumocystis pneumonia (PCP) is a common, usually fatal opportunistic infection of HIV-infected infants. This review summarizes the current knowledge and recommended practices regarding PCP prophylaxis in HIV-exposed infants. The incidence of PCP has dropped dramatically in areas of the world where widespread testing for HIV and empiric prophylaxis for PCP in HIV-exposed neonates have been adopted. The recommended drug for PCP prophylaxis is trimethoprim-sulfamethoxazole (TMP-SMX), and all HIV-infected infants under a year of age should receive PCP prophylaxis as well as combination anti-retroviral therapy. With the advent of accurate, timely testing that can reliably rule out infection with HIV at an early age, PCP prophylaxis can be safely avoided in the majority of HIV-exposed infants. Resource-poor settings should employ universal PCP prophylaxis for HIV-exposed infants and have a need for rapid, accurate, molecular testing approaches to diagnose HIV infection in exposed neonates.

Keywords: pneumocystis, jirovecii, PCP, HIV, prophylaxis, neonate

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]